Henrickson Nauta Wealth Advisors Inc. Acquires 7,074 Shares of Gilead Sciences, Inc. $GILD

Henrickson Nauta Wealth Advisors Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 100.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,125 shares of the biopharmaceutical company’s stock after purchasing an additional 7,074 shares during the period. Henrickson Nauta Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $1,714,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Brighton Jones LLC grew its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC lifted its stake in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares during the period. Wealthspire Advisors LLC lifted its stake in shares of Gilead Sciences by 19.5% in the second quarter. Wealthspire Advisors LLC now owns 2,681 shares of the biopharmaceutical company’s stock worth $297,000 after acquiring an additional 437 shares during the period. Finally, Personal CFO Solutions LLC boosted its holdings in Gilead Sciences by 9.4% in the second quarter. Personal CFO Solutions LLC now owns 4,485 shares of the biopharmaceutical company’s stock valued at $497,000 after acquiring an additional 386 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $137.21 on Friday. The stock has a market capitalization of $170.34 billion, a price-to-earnings ratio of 20.27, a PEG ratio of 1.80 and a beta of 0.37. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The stock’s 50 day moving average price is $142.69 and its two-hundred day moving average price is $127.88. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the business posted $1.90 EPS. Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is presently 48.45%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the insider directly owned 131,779 shares in the company, valued at $19,006,485.17. This trade represents a 2.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 309,280 shares of company stock valued at $44,068,850. 0.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GILD shares. TD Cowen increased their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Truist Financial upped their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Daiwa Securities Group increased their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Argus lifted their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Morgan Stanley upped their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.